EGFR LYTAC (Lycia)

N/A

Report date: 2026/04/27 20:02:09

Base Information

Drug NameEGFR LYTAC (Lycia)
Drug Alias NameN/A
ClassificationBiologics > Lysosome-Targeting Chimaeras (LYTAC)
Mechanisms of ActionEpidermal growth factor receptor erbB1 degraders
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLycia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesLycia Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A